Edgewise Therapeutics (EWTX) Other financing activities (2020 - 2026)

Edgewise Therapeutics has reported Other financing activities for 7 years, with the latest figure at $12.2 million in Q1 2026.

• Quarterly Other financing activities rose 438.39% year-over-year to $12.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.7 million (up 1348.49% YoY) and the FY2025 annual result came in at $7.8 million, up 778.72% from the prior year.
• Other financing activities grew to $12.2 million in Q1 2026 per EWTX's latest filing, from $3.6 million in the prior quarter.
• Over five years, Other financing activities peaked at $12.2 million in Q1 2026 and troughed at -$3.1 million in Q3 2024.
• A 5-year average of $1.3 million and a median of $73000.0 in 2022 frame the typical range for Other financing activities.
• The widest YoY moves for Other financing activities: up 9071.43% in 2024, down 102766.67% in 2024.
• Over 5 years, Other financing activities stood at -$60000.0 in 2022, then jumped by 203.33% to $62000.0 in 2023, then jumped by 650.0% to $465000.0 in 2024, then jumped by 684.95% to $3.6 million in 2025, then surged by 233.51% to $12.2 million in 2026.
• According to Business Quant data, Other financing activities over the past three periods registered $12.2 million, $3.6 million, and $3.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.